Arrowhead Pharmaceuticals (ARWR) Earning Somewhat Positive News Coverage, Study Shows
Headlines about Arrowhead Pharmaceuticals (NASDAQ:ARWR) have trended somewhat positive this week, according to Accern. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Arrowhead Pharmaceuticals earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.0441102401449 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news headlines that may have impacted Accern’s scoring:
- Stock in the Viewfinder: Arrowhead Pharmaceuticals Inc (ARWR) – Bulletin News (orobulletin.com)
- Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Experiences Heavier than Usual Trading Volume (highlightpress.com)
- Arrowhead Pharmaceuticals Inc (ARWR) Sees Schaff Trend Cycle Trending Up – Evergreen Caller (evergreencaller.com)
- Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Traded Well Above Its 50 Day Moving Average – Modern Readers (modernreaders.com)
- Is Arrowhead Pharmaceuticals (ARWR) Worth Significant Investment? – StockNewsGazette (stocknewsgazette.com)
ARWR has been the subject of several research analyst reports. ValuEngine upgraded Arrowhead Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 24th. Piper Jaffray Companies reiterated a “hold” rating and set a $2.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Friday, July 28th. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $2.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Friday, August 4th. One analyst has rated the stock with a sell rating and five have given a hold rating to the company. The stock has a consensus rating of “Hold” and an average price target of $1.80.
Arrowhead Pharmaceuticals (ARWR) opened at 2.80 on Friday. The stock’s market capitalization is $209.36 million. Arrowhead Pharmaceuticals has a 1-year low of $1.20 and a 1-year high of $8.09. The stock’s 50 day moving average price is $1.95 and its 200 day moving average price is $1.81.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.06. The firm had revenue of $9.34 million for the quarter, compared to analyst estimates of $5.29 million. Arrowhead Pharmaceuticals had a negative return on equity of 46.73% and a negative net margin of 201.84%. Equities research analysts forecast that Arrowhead Pharmaceuticals will post ($0.42) earnings per share for the current year.
WARNING: This article was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.watchlistnews.com/arrowhead-pharmaceuticals-arwr-earning-somewhat-positive-news-coverage-study-shows/1535511.html.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
Receive News & Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.